FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant
J. Yu, W. Dong, J. Wang, L. Tian, J. Zhang, H. L. Mead, S. Jaramillo, A. Li, R. Zumwalt, S. P. J. Whelan, E. Settles, P. Keim, B. M. Barker, M. Caligiuri
This study shows FXa cleaves SARS-CoV-2 spike protein, blocking viral entry, but B.1.1.7 variant is resistant, and FXa inhibitors like rivaroxaban reduce this protection.
bioRxiv · Jun 7, 2021 · PreprintMicrobiology